MedTrace Logo

Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy

NCT00703144 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-01-24

No results posted yet for this study

Summary

The pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration.

Conditions

  • Diffusive and Convective Clearance
  • Body Clearance
  • Piperacillin Tazocilline Concentrations (Cmin)

Interventions

DRUG

piperacillin/tazobactam

piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days

PROCEDURE

Pharmacokinetic

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • LAVAYSSIERE Laurence, MD · University Hospital, Toulouse

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703144 on ClinicalTrials.gov